Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Reichl, P; Fang, M; Starlinger, P; Staufer, K; Nenutil, R; Muller, P; Greplova, K; Valik, D; Dooley, S; Brostjan, C; Gruenberger, T; Shen, J; Man, K; Trauner, M; Yu, J; Gao, CF; Mikulits, W.
Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.
Int J Cancer. 2015; 137(2):385-394
Doi: 10.1002/ijc.29394
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Trauner Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- If diagnosed at early stages, patients with hepatocellular carcinoma (HCC) can receive curative therapies, whereas therapeutic options at later stages are very limited. Here, we addressed the potential of soluble Axl (sAxl) as a biomarker of early HCC by analyzing levels of sAxl in 311 HCC and 237 control serum samples from centers in Europe and China. Serum concentrations of sAxl were significantly increased in HCC (18.575 ng/mL) as compared to healthy (13.388 ng/mL) or cirrhotic (12.169 ng/mL) controls. Receiver operating characteristic curve analysis of sAxl in very early stage HCC patients (BCLC 0) showed an area under the curve (AUC) of 0.848, with a sensitivity of 76.9% and a specificity of 69.2%. α-Fetoprotein (AFP)-negative HCC patients displayed an AUC of 0.803, with sensitivity and specificity of 73% and 70.8%. Combination of sAxl and AFP improved diagnostic accuracy to 0.936 in very early HCC patients and to 0.937 in all HCC. Differential diagnosis of very early HCC versus liver cirrhosis showed a combined performance for sAxl and AFP of 0.901 with a sensitivity of 88.5% and a specificity of 76.7%. Furthermore, sAxl levels failed to be elevated in primary ovarian, colorectal and breast carcinomas as well as in secondary hepatic malignancies derived from colon. In summary, sAxl outperforms AFP in detecting very early HCC as compared to healthy or cirrhotic controls and shows high diagnostic accuracy for AFP-negative patients. sAxl is specific for HCC and suggested as a biomarker for routine clinical use. © 2014 UICC.
- Find related publications in this database (using NLM MeSH Indexing)
- Biomarkers, Tumor - blood
- Biomarkers, Tumor - metabolism
- Carcinoma, Hepatocellular - blood
- Carcinoma, Hepatocellular - diagnosis
- Cell Line, Tumor -
- Diagnosis, Differential -
- Early Diagnosis -
- Enzyme-Linked Immunosorbent Assay -
- Female -
- Hep G2 Cells -
- Humans -
- Kaplan-Meier Estimate -
- Liver Cirrhosis - blood
- Liver Cirrhosis - diagnosis
- Liver Neoplasms - blood
- Liver Neoplasms - diagnosis
- Male -
- Middle Aged -
- Neoplasm Staging -
- Proto-Oncogene Proteins - blood
- Proto-Oncogene Proteins - metabolism
- ROC Curve -
- Receptor Protein-Tyrosine Kinases - blood
- Receptor Protein-Tyrosine Kinases - metabolism
- Solubility -
- alpha-Fetoproteins - metabolism
- Find related publications in this database (Keywords)
- soluble Axl
- hepatocellular carcinoma
- biomarker
- alpha-fetoprotein